A prospective pilot study of levetiracetam for body dysmorphic disorder

CNS Spectrums

Volumn 14, Issue 5, 2009, Pages 252-260

  Phillips, Katharine A ^a,b   Menard, William ^a  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMPHETAMINE; BUSPIRONE; CLONAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUVOXAMINE; LITHIUM; TRAZODONE; VENLAFAXINE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PIRACETAM;

ADULT; ANXIETY; ARTICLE; BECK ANXIETY INVENTORY; BEDTIME DOSAGE; BODY DYSMORPHIC DISORDER; BROWN ASSESSMENT OF BELIEFS SCALE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING SCALE; HAMILTON SCALE; HUMAN; INSOMNIA; IRRITABILITY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SOCIAL PHOBIA INVENTORY; SUICIDAL IDEATION; TREATMENT DURATION; YALE BROWN OBSESSIVE COMPULSIVE SCALE MODIFIED FOR BODY DYSMORPHIC DISORDER; BODY IMAGE; DOSE RESPONSE; MIDDLE AGED; PHOBIA; PILOT STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; QUESTIONNAIRE; SATISFACTION; SELF CONCEPT; SOMATOFORM DISORDER; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; ANXIETY; BODY IMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONAL SATISFACTION; PHOBIC DISORDERS; PILOT PROJECTS; PIRACETAM; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SELF CONCEPT; SOMATOFORM DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649888794     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900025414     Document Type: Article

References (55)

1. Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991;148:1138-1149.
2. Faravelli C, Salvatori S, Galassi F, et al. Epidemiology of somatoform disorders: a community survey in Florence. Soc Psychiatry Psychiatr Epidemiol. 1997;32:24-29. (Pubitemid 27029770)
3. Bienvenu OJ, Samuels JF, Riddle MA, et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry. 2000;48:287-293.
4. Koran LM, Abujaoude E, Large MD, Serpe RT. The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr. 2008;13:316-322. (Pubitemid 351656253)
5. Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brahler E. The prevalence of body dysmorphic disorder: a population-based survey. Psychol Med. 2006;36:877-885.
6. Perugi G, Giannotti D, Frare F, et al. Prevalence, phenomenology and comorbidity of body dysmorphic disorder (dysmorphophobia) in a clinical population. Int J Clin Pract. 1997;1:77-82. (Pubitemid 127528175)
7. Phillips KA, Diaz S. Gender differences in body dysmorphic disorder. J Nerv Ment Dis. 1997;185:570-577. (Pubitemid 27431620)
8. Phillips KA, Pagano ME, Menard W, Stout RL. A 12-month follow-up study of the course of body disorder. Am J Psychiatry. 2006;163:907-912. (Pubitemid 44464541)
9. Didie ER, Menard W, Stern AP, Phillips KA. Occupational functioning and impairment in adults with body dysmorphic disorder. Compr Psychiatry. 2008;49:561-569.
10. Phillips KA. Quality of life for patients with body dysmorphic disorder. J Nerv Ment Dis. 2000;188:170-175.
11. Phillips KA, Menard W, Fay C, Pagano M. Psychosocial functioning and quality of life in body dysmorphic disorder. Compr Psychiatry. 2005;46:254-260. (Pubitemid 40814442)
12. Didie ER, Walters MM, Pinto A, et al. Comparison of quality of life and psychosocial functioning in obsessive-compulsive disorder and body dysmorphic disorder. Ann Clin Psychiatry. 2007;19:181-186. (Pubitemid 47345872)
13. Frare F, Perugi G, Ruffolo G, Toni C. Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features. Eur Psychiatry. 2004;19:292-298. (Pubitemid 38987841)
14. Veale D, Boocock A, Gournay K, et al. Body dysmorphic disorder: a survey of fifty cases. Br J Psychiatry. 1996;169:196-201.
15. Phillips KA, Coles M, Menard W, et al. Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry. 2005;66:717-725.
16. Phillips KA, Menard W. Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry. 2006;163:1280-1282. (Pubitemid 44464459)
17. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image. 2008;5:13-27.
18. National Collaborating Centre for Mental Health. Obsessive Compulsive Disorder: Core Interventions in the Treatment of Obsessive Compulsive Disorder and Body Dysmorphic Disorder. National Clinical Practice Guideline Number 31. London, Disorder British Psychiatric Society and Royal College of Psychiatrists; 2006.
19. Hollander E, Allen A, Kwon J, et al. Clomipramine versus desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56:1033-1039. (Pubitemid 29526387)
20. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59:381-388. (Pubitemid 34275257)
21. Perugi G, Giannotti D, Di Vaio S, et al. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11:247-254. (Pubitemid 27049289)
22. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59:165-171. (Pubitemid 28208330)
23. Phillips KA, Najjar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64:715-720. (Pubitemid 36750151)
24. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21:177-179. (Pubitemid 43740309)
25. Allen A, Hadley SJ, Kaplan A, et al. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008;13:138-144.
26. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101:9861-9866.
27. Rigo JM, Hans G, Nguyen L, et al. The anti-epilepetic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-A and glycinegated currents. Br J Pharmacol. 2002;136:659-672. (Pubitemid 34785708)
28. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65:1219-1222.
29. Coles ME, Phillips KA, Menard W, et al. Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety. 2006;23:26-33. (Pubitemid 43297365)
30. Pinto A, Phillips KA. Social anxiety in body dysmorphic disorder. Body Image. 2005;2:401-405. (Pubitemid 43024716)
31. Kelly MM, Walters C, Phillips KA. Social anxiety and its relationship to functional impairment in body dysmorphic disorder. Behav Ther. In press.
32. Wilhelm S, Otto MW, Zucker BG, Pollack MH. Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord. 1997;11:499-502. (Pubitemid 127363439)
33. Buhlmann U, Wilhelm S, McNally RJ, et al. Interpretive biases for ambiguous information in body dysmorphic disorder. CNS Spectr. 2002;7:435-436;441-443. (Pubitemid 34761854)
34. Gunstad J, Phillips KA. Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry. 2003;44:270-276. (Pubitemid 36875460)
35. Phillips KA, Menard W, Fay C, Weisberg R. Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics. 2005;46:317-332.
36. Zhang W, Connor KM, Davidson JRT. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005;19:551-553. (Pubitemid 41392309)
37. Grunze HC. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci. 2008;10:77-89.
38. Phillips KA, Hollander E, Rasmussen SA, et al. A severity rating scale for body dysmorphic disorder. Psychopharmacol Bull. 1997;33:17-22.
39. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, New York: Biometrics Research, New York State Psychiatric Institute; 2002.
40. National Institute of Mental Health. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull. 1985;21:839.
41. Eisen JL, Phillips KA, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry. 1998;155:102-108. (Pubitemid 28037556)
42. Miller IW, Bishop S, Norman WH, Maddever H. The modified Hamilton Rating Scale for depression: reliability and validity. Psychiatry Res. 1985;14:131-142. (Pubitemid 15138581)
43. Connor KM, Davidson JRT, Churchill LE, et al. Psychometric properties of the Social Phobia Inventory (SPIN). Br J Psychiatry. 2000;176:379-386.
44. Shear MK, Brown B, Clark DB. Anxiety disorder measures. In: Rush AJ, First MB, Blacker D, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2007:529-558.
45. Brown GK, Beck AT, Newman CF, Beck JS, Tran GQ. A comparison of focused and standard cognitive therapy for panic disorder. J Anxiety Disord. 1997;11:329-345.
46. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
47. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321-326. (Pubitemid 23311543)
48. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
49. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001;62:721-727. (Pubitemid 32994936)
50. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162:1171-1178. (Pubitemid 40770701)
51. Phillips KA, Kaye WH. The relationship of body dysmorphic disorder and eating disorders to obsessive-compulsive disorder. CNS Spectr. 2007;12:347-358. (Pubitemid 46867550)
52. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders. J Clin Psychopharmacol. 2007;27:263-272.
53. Mazza M, Martini A, Scoppetta M, Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:539-543. (Pubitemid 351178974)
54. Kinrys G, Worthington JJ, Wygant L, et al. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007;68:1010-1013. (Pubitemid 47340319)
55. Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006;67:211-214. (Pubitemid 43357466)